{"denoms":[{"counts":[{"groupId":"BG000","value":"308"},{"groupId":"BG001","value":"309"},{"groupId":"BG002","value":"617"}],"units":"Participants"}],"groups":[{"description":"On Day 1 of each 21-day cycle, participants received an intravenous (IV) infusion of pembrolizumab 200 mg for up to 35 cycles (up to approximately 2 years) PLUS Investigator choice of chemotherapy for up to 6 cycles (paclitaxel 175 mg/m\\^2 PLUS cisplatin 50 mg/m\\^2 WITH or WITHOUT bevacizumab 15 mg/kg per local label OR paclitaxel 175 mg/m\\^2 PLUS carboplatin Area Under the Curve (AUC) 5 for up to 6 cycles, WITH or WITHOUT bevacizumab 15 mg/kg per local label). All treatments were administered until disease progression or toxicity. Eligible participants who stopped the initial course of pembrolizumab with Stable Disease (SD) or better but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.","id":"BG000","title":"Pembrolizumab+Chemotherapy"},{"description":"On Day 1 of each 21-day cycle, participants received an IV infusion of placebo (Normal Saline or Dextrose solution) for up to 35 cycles (up to approximately 2 years) PLUS Investigator choice of chemotherapy for up to 6 cycles (paclitaxel 175 mg/m\\^2 PLUS cisplatin 50 mg/m\\^2 WITH or WITHOUT bevacizumab 15 mg/kg per local label OR paclitaxel 175 mg/m\\^2 PLUS carboplatin AUC 5 for up to 6 cycles, WITH or WITHOUT bevacizumab 15 mg/kg per local label). All treatments were administered until disease progression or toxicity.","id":"BG001","title":"Placebo+Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.9","value":"51.7"},{"groupId":"BG001","spread":"12.7","value":"50.7"},{"groupId":"BG002","spread":"12.3","value":"51.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"308"},{"groupId":"BG001","value":"309"},{"groupId":"BG002","value":"617"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"109"},{"groupId":"BG001","value":"121"},{"groupId":"BG002","value":"230"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"193"},{"groupId":"BG001","value":"184"},{"groupId":"BG002","value":"377"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"10"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"39"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"110"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"170"},{"groupId":"BG001","value":"190"},{"groupId":"BG002","value":"360"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"66"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"36"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"69"}]}],"title":"PD-L1 CPS<1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"116"},{"groupId":"BG002","value":"231"}]}],"title":"1≤ PD-L1 CPS<10"},{"categories":[{"measurements":[{"groupId":"BG000","value":"158"},{"groupId":"BG001","value":"159"},{"groupId":"BG002","value":"317"}]}],"title":"PD-L1 CPS≥10"}],"description":"Participants were assessed for their PD-L1 tumor expression level by immunohistochemistry assay using tumor tissue. Randomization of participants in the study were stratified by their PD-L1 CPS at baseline (PD-L1 CPS\\<1, 1≤ PD-L1 CPS\\<10, or PD-L1 CPS≥10).","paramType":"COUNT_OF_PARTICIPANTS","title":"Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"94"},{"groupId":"BG001","value":"96"},{"groupId":"BG002","value":"190"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"214"},{"groupId":"BG001","value":"213"},{"groupId":"BG002","value":"427"}]}],"title":"No"}],"description":"Randomization of participants was stratified by whether they were metastatic at initial diagnosis (Yes or No). Metastatic was defined as Stage IVB based on the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) (2009).","paramType":"COUNT_OF_PARTICIPANTS","title":"Metastatic at Initial Diagnosis","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"196"},{"groupId":"BG001","value":"193"},{"groupId":"BG002","value":"389"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"112"},{"groupId":"BG001","value":"116"},{"groupId":"BG002","value":"228"}]}],"title":"No"}],"description":"Randomization of participants was stratified by the Investigator's choice for the participant to receive bevacizumab (Yes or No).","paramType":"COUNT_OF_PARTICIPANTS","title":"Investigator Choice to Use Bevacizumab","unitOfMeasure":"Participants"}]}